Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2023 | Biomarkers in DLB trials

Carla Abdelnour, PhD, Stanford University, Palo Alto, CA, discusses the importance of accounting for co-pathologies during clinical trials, particularly the co-pathologies of dementia with Lewy bodies (DLB) and Alzheimer’s disease. DLB is characterized by Lewy pathology but is commonly found to coexist with Alzheimer’s disease, as well as other co-morbidities. Dr Abdelnour advocates for greater accountability for co-pathologies in the design of clinical trials and the selection of participants, to allow for personalized therapies. Furthermore, she supports the inclusion of biofluid biomarkers to assist in the development of disease modifying therapies for DLB. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2023 in Amsterdam, Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Carla Abdelnour has received the Sue Berghoff LBD Research Fellowship, and honoraria as speaker from F. Hoffmann-La Roche Ltd, Zambon, Nutricia, Schwabe Farma Ibérica S.A.U. She is member of the Board of Directors of the Lewy Body Dementia Association.